Cytosorbents Corporation (NASDAQ: CTSO) is one of 82 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it contrast to its peers? We will compare Cytosorbents Corporation to related companies based on the strength of its dividends, profitability, institutional ownership, risk, earnings, valuation and analyst recommendations.
Volatility and Risk
Cytosorbents Corporation has a beta of -0.52, suggesting that its stock price is 152% less volatile than the S&P 500. Comparatively, Cytosorbents Corporation’s peers have a beta of 0.89, suggesting that their average stock price is 11% less volatile than the S&P 500.
Earnings & Valuation
This table compares Cytosorbents Corporation and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Cytosorbents Corporation||$12.18 million||-$10.41 million||-17.08|
|Cytosorbents Corporation Competitors||$2.02 billion||$430.74 million||-66.50|
Cytosorbents Corporation’s peers have higher revenue and earnings than Cytosorbents Corporation. Cytosorbents Corporation is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This table compares Cytosorbents Corporation and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cytosorbents Corporation Competitors||-328.00%||-35.87%||-12.56%|
Insider & Institutional Ownership
6.9% of Cytosorbents Corporation shares are held by institutional investors. Comparatively, 51.0% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 5.6% of Cytosorbents Corporation shares are held by company insiders. Comparatively, 18.6% of shares of all “Advanced Medical Equipment & Technology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This is a summary of current ratings and recommmendations for Cytosorbents Corporation and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cytosorbents Corporation Competitors||255||1817||3259||105||2.59|
Cytosorbents Corporation presently has a consensus target price of $10.45, indicating a potential upside of 69.92%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 5.76%. Given Cytosorbents Corporation’s stronger consensus rating and higher probable upside, equities analysts clearly believe Cytosorbents Corporation is more favorable than its peers.
Cytosorbents Corporation peers beat Cytosorbents Corporation on 8 of the 12 factors compared.
Cytosorbents Corporation Company Profile
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.
Receive News & Ratings for Cytosorbents Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corporation and related companies with MarketBeat.com's FREE daily email newsletter.